Your new experience awaits. Try the new design now and help us make it even better

MINI REVIEW article

Front. Cell. Neurosci.

Sec. Cellular Neuropathology

This article is part of the Research TopicNeurodevelopmental disorders: current research status and future challengesView all 4 articles

The dopaminergic system in neurodevelopment: preclinical models of neurodevelopmental disorders and susceptibility to neurodegeneration

Provisionally accepted
  • 1University of Cagliari, Cagliari, Italy
  • 2Universita degli Studi di Cagliari, Cagliari, Italy

The final, formatted version of the article will be published soon.

The dopaminergic system plays a pivotal role in neurodevelopment, guiding the formation and refinement of neural circuits underlying salience attribution, cognition, reward and aversion. Its maturation extends from prenatal life through adolescence and may be influenced by genetic and environmental factors. Evidence from preclinical models suggests that perturbations during these sensitive windows may alter neurodevelopmental trajectories toward maladaptive outcomes, increasing vulnerability to neurodevelopmental disorders. This mini-review synthesizes findings from animal models to examine how physiological dopaminergic maturation might be shaped by genetic, as well as environmental, factors. We discussed maternal immune activation, prenatal cannabis exposure, and genetic models directly targeting dopaminergic function, all of which underscore the critical role of dopamine dysregulation in shaping neurodevelopmental outcomes. Beyond neurodevelopmental disorders, we extend this framework to newly emerging evidence concerning how early-life dopaminergic perturbations may influence dopamine system resilience and predispose individuals to accelerated cognitive decline and neurodegenerative disorders. Midbrain dopamine neurons exhibit intrinsic vulnerabilities that may render them especially sensitive to cumulative developmental and aging-related stressors and may serve as early predictors of disease. Finally, we discuss the therapeutic implications, emphasizing the limited mechanistic innovation in current pharmacological treatments and the growing need to target upstream or convergent developmental mechanisms in order to modify disease trajectories before overt dopaminergic dysfunction becomes established.

Keywords: Alzheimer's disease (AD), Attention Deficit Hyperactivity Disorder (ADHD), Autism spectrum disorders (ASD), Maternal immune activation (MIA), mesocorticolimbic system, Parkinson Disease (PD), Schizophrenia, ventral tegmental area (VTA)

Received: 07 Jan 2026; Accepted: 09 Feb 2026.

Copyright: © 2026 Santoni, Mastio, Pistis and Sagheddu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Claudia Sagheddu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.